Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALIS in newly diagnosed MAC lung infection
NCT04677569Phase 3Completed
- Sponsor
- Insmed Incorporated
- Start
- Apr 2021
- Primary completion
- Nov 2025
- Modality
- Small Molecules, Lipid-based Nanoparticles
- Countries
- 23
01
Overview
A Phase 3 trial of amikacin liposome inhalation suspension in Nontuberculous Mycobacterial Lung Disease (NTM-LD), sponsored by Insmed Incorporated. Started Apr 2021; status: completed.
02
Drugs
amikacin liposome inhalation suspension
03
Conditions
Nontuberculous Mycobacterial Lung Disease (NTM-LD)
Beyond the preview
Go deeper on NCT04677569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04677569.